In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in Klebsiella aerogenes.

IF 4.1 2区 医学 Q2 MICROBIOLOGY
Antimicrobial Agents and Chemotherapy Pub Date : 2024-12-05 Epub Date: 2024-11-06 DOI:10.1128/aac.01307-24
Salud Rodríguez-Pallares, Tania Blanco-Martín, Emilio Lence, Pablo Aja-Macaya, Lucía Sánchez-Peña, Lucía González-Pinto, María Rodríguez-Mayo, Ana Fernández-González, Fátima Galán-Sánchez, Alejandro Beceiro, Concepción González-Bello, Germán Bou, Jorge Arca-Suárez
{"title":"<i>In vivo</i> emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in <i>Klebsiella aerogenes</i>.","authors":"Salud Rodríguez-Pallares, Tania Blanco-Martín, Emilio Lence, Pablo Aja-Macaya, Lucía Sánchez-Peña, Lucía González-Pinto, María Rodríguez-Mayo, Ana Fernández-González, Fátima Galán-Sánchez, Alejandro Beceiro, Concepción González-Bello, Germán Bou, Jorge Arca-Suárez","doi":"10.1128/aac.01307-24","DOIUrl":null,"url":null,"abstract":"<p><p>We describe the <i>in vivo</i> emergence of resistance to ceftazidime/avibactam via modification of AmpC in a clinical <i>Klebsiella aerogenes</i> isolate during therapy with this combination. Paired ceftazidime/avibactam-susceptible/resistant isolates were obtained before and during ceftazidime/avibactam treatment. Whole genome sequencing revealed a differential mutation in AmpC (R148W) in the ceftazidime/avibactam-resistant isolate. Molecular cloning and structural studies confirmed the impact of this substitution, which affects the architecture of the H10 helix, on the evolved resistant phenotype.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0130724"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619368/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01307-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We describe the in vivo emergence of resistance to ceftazidime/avibactam via modification of AmpC in a clinical Klebsiella aerogenes isolate during therapy with this combination. Paired ceftazidime/avibactam-susceptible/resistant isolates were obtained before and during ceftazidime/avibactam treatment. Whole genome sequencing revealed a differential mutation in AmpC (R148W) in the ceftazidime/avibactam-resistant isolate. Molecular cloning and structural studies confirmed the impact of this substitution, which affects the architecture of the H10 helix, on the evolved resistant phenotype.

通过改变产气克雷伯氏菌染色体上的 AmpC β-内酰胺酶,在体内产生对头孢他啶/阿维菌素的耐药性。
我们描述了在使用头孢他啶/阿维巴坦联合疗法的过程中,临床产气克雷伯氏菌分离株通过改变AmpC对头孢他啶/阿维巴坦产生耐药性的情况。在头孢他啶/阿维巴坦治疗前和治疗期间,获得了成对的头孢他啶/阿维巴坦易感/耐药分离株。全基因组测序显示,耐头孢他啶/阿维菌素的分离株中的AmpC发生了差异突变(R148W)。分子克隆和结构研究证实了这一影响 H10 螺旋结构的置换对进化耐药表型的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.00
自引率
8.20%
发文量
762
审稿时长
3 months
期刊介绍: Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信